Only a small percentage of cancer patients have access to genomic biomarker information that could help match them with targeted treatments demonstrated to improve outcomes. By working with local laboratories to insource NGS oncology assays, we support your efforts to deliver equitable access to precision oncology.
Through Project ACTT, Canexia Health is speeding up cancer testing for targeted treatment selection during and beyond COVID-19 through a minimally invasive circulating tumor (ctDNA) DNA assay. The assay, which requires a blood sample, is available as an alternative to some surgical tissue biopsies for patients with advanced lung, breast, or colorectal cancer
We pair the latest advances in oncology with machine learning to provide cancer researchers and professionals with the insights needed to make informed decisions
“We have found the FIND-IT assay to be a reliable, quick and cost-effective tool for identifying driver mutations in fixed tissue samples from across Australia. This has had direct implications for identifying patients suitable for targeted therapies, especially those with lung cancer, colorectal cancer and melanoma. However, the scope of the test is such that there is also interest in the panel for patients with a variety of other cancers, including breast and endometrial cancers.” Professor Graeme Suthers, Sonic Genetics
Tailor treatment decisions based on somatic mutations in your patient’s tumor.
A minimally invasive option for biopsy, Follow It can also be used to monitor cancer progression or investigate treatment resistance.
Rapid, cost-effective, and clinically actionable, Fusions allows you the flexibility to isolate and interrogate relevant fusions.
Make more informed treatment decisions by using detailed results for therapeutic recommendations and expertly curated clinical trials information provided in our comprehensive reporting software.
Perform sophisticated NGS oncology profiling right from your laboratory without the large upfront investment. Pairing our cloud-based analytics, interpretation, and reporting platform allows partner labs access to our proprietary informatics software suite. This suite covers the full stack of molecular and computational quality assurance, genome analytics, mutation interpretation, and report generation.
May 19, 2021
The California health system is working with Canexia to assess if a triaged, in-house testing strategy improves outcomes, lowers cost, and reduces access inequities.
May 4, 2021
Microsatellites are short, repeating DNA segments that can play a major role in studying cancers.
April 20, 2021
Precision medicine instruments produce incredible amounts of data, sometimes measured in terabytes or even petabytes.
Contact us today to learn about our end-to-end solution, from mutation identification to auto-generated clinical reports.